Opinion
Video
Author(s):
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy
Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase
CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL
Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma